Search

Your search keyword '"Alcino S."' showing total 2 results
Start Over Author "Alcino S." Topic biological therapy
2 results on '"Alcino S."'

1. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update.

Author

Fonseca JE, Canhão H, Reis P, Santos MJ, Branco J, Quintal A, Malcata A, Araújo D, Ventura F, Figueiredo G, da Silva JC, Patto JV, de Queiroz MV, Santos RA, Neto AJ, de Matos Ad, Rodrigues A, Mourão AF, Ribeiro AS, Cravo AR, Barcelos A, Cardoso A, Vilar A, Braña A, Faustino A, Silva C, Godinho F, Cunha I, Costa JA, Gomes JA, Pinto JA, da Silva JA, Miranda LC, Inês L, Santos LM, Cruz M, Salvador MJ, Ferreira MJ, Rial M, Bernardes M, Bogas M, Araújo P, Machado P, Pinto P, de Melo RG, Cortes S, Alcino S, and Capela S

Subjects
Humans, Arthritis, Rheumatoid drug therapy, Biological Therapy
Abstract

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, characterized by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of 0.6 in the DAS28 score. After 6 months of treatment response criteria is defined as a decrease of more than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).

Published
2010

2. Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update

Author

Fonseca, J. E., Canhão, H., Reis, P., Santos, M. J., Branco, J., Quintal, A., Malcata, A., Araújo, D., Ventura, F., Figueiredo, G., Da Silva, J. C., Patto, J. V., Queiroz, M. V., Santos, R. A., Neto, A. J., Matos, A., Rodrigues, A., Mourão, A. F., Ribeiro, A. S., Cravo, A. R., Anabela Barcelos, Cardoso, A., Vilar, A., Braña, A., Faustino, A., Silva, C., Godinho, F., Cunha, I., Costa, J. A., Gomes, J. A., Pinto, J. A., Da Silva, J. A., Miranda, L. C., Inês, L., Santos, L. M., Cruz, M., Salvador, M. J., Ferreira, M. J., Rial, M., Bernardes, M., Bogas, M., Araújo, P., Machado, P., Pinto, P., Melo, R. G., Cortes, S., Alcino, S., Capela, S., and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
Arthritis, Rheumatoid, Biological Therapy, musculoskeletal diseases, Anti-TNF, Abatacept, Rheumatology, Humans, Artrite Reumatóide, Tocilizumab, skin and connective tissue diseases, Rituximab, Terapêutica Biológica
Abstract

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, characterized by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of 0.6 in the DAS28 score. After 6 months of treatment response criteria is defined as a decrease of more than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab). publishersversion published

Catalog

Books, media, physical & digital resources
See catalog results